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IntroductIon
Diseases characterized by ischemia affecting the brain, retina, 
heart, and limb significantly impact human health, and the 
therapeutic induction of blood vessel growth by delivery of 
the vascular endothelial growth factor (VEGF) has the poten-
tial to alleviate tissue ischemia (Potente et al., 2011). However, 
VEGF also increases vascular hyperpermeability, both acutely 
at injury sites and over prolonged periods in chronic con-
ditions with associated edema; for example, in neovascular 
eye disease, pulmonary vascular disease, and cancer (Ma et al., 
2012; Greenberg and Jin, 2013; Barratt et al., 2014). To date, 
a poor understanding of the molecular mechanisms that dis-
tinguish VEGF-mediated permeability from other VEGF re-
sponses has hampered the design of therapies that selectively 
target VEGF-induced vessel leak and therefore edema.
The tyrosine kinase receptor VEG FR2 has been im-
plicated as the main VEGF receptor in endothelial perme-
ability signaling in various organs, including the lung, skin, 
and brain (Murohara et al., 1998; Weis et al., 2004; Weis and 
Cheresh, 2005; Sun et al., 2012; Hudson et al., 2014; Li et al., 
2016). In response to VEGF, VEG FR2 activates SRC family 
kinases (SFKs) and the ABL kinases ABL1 and ABL2 (also 
known as ARG) to mediate VEGF-induced vascular perme-
ability (Eliceiri et al., 1999; Aman et al., 2012; Anselmi et 
al., 2012; Sun et al., 2012; Chislock and Pendergast, 2013). 
However, a VEGF mutant with low VEG FR2 affinity retains 
the ability to evoke intradermal vascular hyperpermeability 
(Stacker et al., 1999), raising the possibility that VEG FR2 ei-
ther recruits a VEGF-binding co-receptor or that VEGF can 
engage an alternative receptor for permeability signaling. 
In humans, VEGF is made as three main isoforms termed 
VEGF121, VEGF165, and VEGF189, with VEGF165 con-
sidered the most pathological VEGF isoform (Usui et al., 
2004). In addition to having a strong affinity for extracellular 
matrix, VEGF165 also differs from VEGF121 by its ability 
to bind neuropilin 1 (NRP1), a noncatalytic co-receptor 
that forms VEGF165-dependent complexes with VEG FR2 
in endothelial cells (ECs; Soker et al., 1998). Complexes are 
then trafficked into signaling endosomes, thereby protecting 
VEG FR2 from premature dephosphorylation and enabling 
sustained activation of the ERK1 and ERK2 kinases for ar-
teriogenesis (Lanahan et al., 2013).
the vascular endothelial growth factor (VEGF) isoform VEGF165 stimulates vascular growth and hyperpermeability. Whereas 
blood vessel growth is essential to sustain organ health, chronic hyperpermeability causes damaging tissue edema. By combin-
ing in vivo and tissue culture models, we show here that VEGF165-induced vascular leakage requires both VEG Fr2 and nrP1, 
including the VEGF164-binding site of nrP1 and the nrP1 cytoplasmic domain (ncd), but not the known ncd interactor 
GIPc1. In the VEGF165-bound receptor complex, the ncd promotes ABL kinase activation, which in turn is required to activate 
VEG Fr2-recruited Src family kinases (SFKs). these results elucidate the receptor complex and signaling hierarchy of down-
stream kinases that transduce the permeability response to VEGF165. In a mouse model with choroidal neovascularisation akin 
to age-related macular degeneration, ncd loss attenuated vessel leakage without affecting neovascularisation. these findings 
raise the possibility that targeting nrP1 or its ncd interactors may be a useful therapeutic strategy in neovascular disease to 
reduce VEGF165-induced edema without compromising vessel growth.
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NRP1 has also been implicated in vascular permeability 
signaling (Raimondi et al., 2016). Intradermal vascular leakage 
induced by VEGF164, the murine equivalent of VEGF165, is 
defective in mice lacking endothelial NRP1 expression, even 
though they retain VEG FR2 (Acevedo et al., 2008). Agreeing 
with an important role for NRP1 in VEGF164-induced vas-
cular permeability, a peptide blocking VEGF164 binding to 
NRP1 inhibits serum albumin leak in a mouse model of di-
abetic retinal injury (Wang et al., 2015), and function-block-
ing antibodies for NRP1 suppress intradermal vascular leak 
induced by VEGF164 injection (Teesalu et al., 2009), as well 
as VEGF164-induced pulmonary vascular leak (Becker et al., 
2005). However, other studies have argued against an import-
ant role for NRP1 in VEGF-induced vascular permeability, 
with one study showing that an antibody blocking VEGF164 
binding to NRP1 impaired corneal neovascularisation, but 
not VEGF164-induced intradermal vascular permeability in 
mice (Pan et al., 2007), and another study finding that NRP1 
deletion does not impair VEGF164-induced permeability of 
retinal vasculature (Cerani et al., 2013). Additionally, C-end-
Rule peptides, which bind NRP1, can induce permeability 
independently of VEG FR2 activation (Roth et al., 2016). The 
relative importance of VEG FR2 and NRP1 for VEGF-in-
duced vascular permeability signaling has therefore remained 
unclear. Moreover, it is not known how NRP1 function may 
intersect with ABL kinase or SFK activation and whether 
these downstream kinases operate in a regulatory hierarchy to 
convey permeability signals.
Here, we have compared VEGF164-induced intrader-
mal vascular leakage in a comprehensive range of mouse mu-
tants to conclusively demonstrate an absolute requirement for 
VEG FR2 and a strong dependency on NRP1, including its 
VEGF164-binding pocket and the NRP1 cytoplasmic do-
main (NCD). We further show that endothelial NRP1 and 
the NCD are required for VEGF165-induced SFK phos-
phorylation, which also depends on the VEG FR2-depen-
dent activation of ABL kinases upstream of SFK activation. 
Moreover, in a mouse model of VEGF-dependent neovascu-
lar pathology akin to exudative age-related macular degener-
ation, NCD-deficient mice had significantly reduced ocular 
vascular leakage, but neovascularisation was unchanged. To-
gether, our findings suggest that targeting the NCD-mediated 
signaling pathway may provide a novel therapeutic strategy 
to selectively treat VEGF165-induced vascular leak without 
compromising other VEGF functions.
rESuLtS
VEGF164-induced vascular leakage depends on VEG Fr2, 
nrP1, and VEGF-binding to nrP1
NRP1 is expressed in developing and pathological blood ves-
sels to promote angiogenesis (Fantin et al., 2013; Raimondi et 
al., 2014; Aspalter et al., 2015). To determine whether NRP1 
expression is maintained in quiescent endothelium, we per-
formed whole mount immunolabeling of adult mouse der-
mis and retina with a previously validated antibody for NRP1 
(Fantin et al., 2010). In both tissues, NRP1 localized to PEC 
AM1-positive capillaries, arteries, and veins, including venules 
(Fig. 1, A and B), consistent with a role for NRP1 in regulat-
ing vascular permeability. Moreover, NRP1 in dermal (Fig. 1, 
A and C’) and retinal (Fig. 1, B and C’’) venules appeared to 
be concentrated in areas enriched for the adherens junction 
proteins PEC AM1 and CDH5 (VE-cadherin).
To directly compare the genetic requirement of NRP1 
and VEG FR2 for VEGF164-induced vascular permeability, 
we used the Miles assay, which measures the extravasation of 
Evans blue–labeled serum albumin after intradermal injection 
of permeability-enhancing agents (Miles and Miles, 1952; 
Senger et al., 1983; Brkovic and Sirois, 2007). In this assay, 
VEGF induces vascular permeability independently of its ef-
fect on systemic blood pressure (Li et al., 2016). As previously 
shown (Aman et al., 2012; Sun et al., 2012; Li et al., 2016), 
wild-type mice exhibited prominent dye leakage 20 min after 
injection of VEGF164, but little or no dye leakage after PBS 
injection (Fig. 2 A). In contrast to their control littermates, 
endothelial Vegfr2-null mice did not respond to VEGF164 
injection with increased vessel leakage (Fig. 2 B). Endothe-
lial Nrp1-null mice also showed a significant reduction in 
VEGF164-induced leakage compared with littermate con-
trols, but, unlike endothelial Vegfr2-null mice, had a residual 
response (Fig. 2 C). Both NRP1 and VEG FR2 are therefore 
essential for VEGF164-induced vascular permeability, with 
VEG FR2 being absolutely required and NRP1 making an 
indispensable contribution for a robust response.
We next examined whether VEGF164 binding to NRP1 
is required for permeability induction. For these experiments, 
we performed Miles assays with two strains of mice lacking 
VEGF164 binding to NRP1 (Fig. 2 D), i.e., mice with homo-
zygous Y297A or D320K mutations, as previously described 
(Fantin et al., 2014; Gelfand et al., 2014). Nrp1Y297A/Y297A mice 
had significantly impaired VEGF164-induced permeability 
(Fig. 2 E). As these mice have reduced NRP1 levels in addition 
to defective VEGF164 binding (Fantin et al., 2014), we also 
examined Nrp1+/− mice with reduced NRP1 levels (Fantin 
et al., 2015). Unlike Nrp1Y297A/Y297A mice, Nrp1+/− mice 
showed similar VEGF164-induced leakage as littermate wild-
type controls (Fig. 2 F). Moreover, Nrp1D320K/D320K mice with 
normal NRP1 levels (Fig. 2 G) also had significantly reduced 
VEGF164-induced permeability (Fig. 2 G).
Together, our findings are compatible with a model in 
which VEGF164 binding to NRP1 induces complex for-
mation between NRP1 and VEG FR2 (Soker et al., 2002) 
to create an obligate holoreceptor in which VEG FR2 is re-
quired, but depends on NRP1 to evoke a maximal permea-
bility response to VEGF164.
VEGF164-induced vascular leakage depends 
on the ncd, but not GIPc1
As GIPC1 (synectin) promotes complex formation be-
tween NRP1 and VEG FR2 (Prahst et al., 2008), and 
NRP1 promotes VEGF164-induced arteriogenesis by re-
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cruiting GIPC1 to the NCD (Lanahan et al., 2013), we 
next asked whether GIPC1 binding to the NCD is also re-
quired for VEGF164-induced vascular leakage (Fig. 3 A). 
However, mice lacking GIPC1 (Chittenden et al., 2006) 
showed similar VEGF164-induced vascular leakage com-
pared with their control littermates (Fig.  3  B). In con-
trast, Nrp1cyto/cyto mice expressing a mutant form of NRP1 
lacking the NCD (Fantin et al., 2011) showed signifi-
cantly reduced VEGF164-induced dye leakage compared 
with controls (Fig. 3 C), similar to endothelial Nrp1-null, 
Nrp1Y297A/Y297A, and Nrp1D320K/D320K mutants. The finding 
that NRP1 promotes vascular leakage through the NCD 
independently of GIPC1 distinguishes permeability from 
arteriogenic VEGF signaling, despite a shared dependence 
of both responses on the NCD.
the ncd is dispensable for SEMA3A- and histamine-
induced vascular permeability
As SEMA3A signals through NRP1 to induce vascular leak-
age in the skin and retina (Acevedo et al., 2008; Cerani et al., 
2013), we next examined whether SEMA3A-induced vascu-
lar permeability was also NCD-dependent. However, dye ex-
travasation in response to SEMA3A was similar in Nrp1cyto/cyto 
and wild-type littermates (Fig. 3 D). These observations are 
consistent with prior findings in the nervous system, where 
SEMA3A binds NRP1, but recruits a plexin co-receptor that 
can transduce signals independently of the NCD (Epstein et 
al., 2015). Histamine acts via G-protein coupled receptors to 
induce vascular hyperpermeability in many inflammatory set-
tings (Miles and Miles, 1952). Similar to SEMA3A, histamine 
increased dye leakage similarly in Nrp1cyto/cyto and wild-type 
Figure 1. nrP1 localization in adult vas-
cular endothelium. Whole-mount immunos-
taining of adult mouse ear dermis for NRP1, 
PEC AM1, and SMA (A) and adult mouse retina 
for NRP1, PEC AM1, and CDH5 (B), including 
control staining for the secondary antibodies 
used to detect NRP1 (anti–goat) and CDH5 
(anti–rabbit), together with the primary and 
secondary antibody for PEC AM1 (three inde-
pendent experiments). Arrowheads indicate 
examples of endothelial junctions sites en-
riched for NRP1 in venules. a, artery; v, vein. 
(C) Single optical sections from the boxed 
areas in A and C’ and B and C’’ were analyzed 
for pixel intensity along a virtual line crossing 
the blood vessel. Bars, 50 µm.
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mice (Fig. 3 E). The NCD is therefore specifically important 
for vascular hyperpermeability in response to VEGF164.
the ncd is not required to maintain the baseline 
vascular barrier to serum leak
To determine whether NCD loss alters baseline vascular per-
meability to serum proteins, we injected Evans Blue into the 
circulation of Nrp1cyto/cyto mice and wild-type littermate con-
trols. After 24 h, dye extravasation was low in the brain due 
to the tight blood–brain–barrier, high in the kidney with its 
endothelial fenestrations and intermediate in organs such as 
the heart and the ear skin, with similar dye extravasation in 
both genotypes (Fig.  3  F). Together with our observations 
in the Miles assay, these findings suggest that NCD loss does 
not obviously alter the endothelial barrier to serum proteins 
under physiological circumstances, but is selectively required 
for the acute hyperpermeability response to VEGF164.
nrP1 promotes VEGF165-induced SFK activation
Two SFK members, SRC and YES1, are tyrosine phosphor-
ylated to transduce signals important for VEGF165-induced 
vascular permeability (Eliceiri et al., 1999; Scheppke et al., 
2008). We therefore examined the requirement of NRP1 for 
VEGF165-induced SFK activation in human dermal micro-
vascular ECs (HDM ECs), which are known to form mono-
layers with relatively well-organized intercellular contacts 
(Kluger et al., 2013). Immunostaining of confluent, nonper-
meabilized HDM ECs in normal growth conditions showed 
NRP1 localization on the cell surface, including areas of cell–
cell contact (Fig. 4 A). Immunostaining for NRP1 and an in-
tracellular epitope of CDH5 after permeabilization confirmed 
localization of a NRP1 subset to areas of cell–cell contact in 
HDM ECs (Fig. 4 B), similar to the pattern observed in skin 
and retinal vasculature (Fig. 1, A and B). We next performed 
immunostaining with an antibody raised against the phos-
phorylated tyrosine (Y) 419 of activated SRC that also rec-
ognizes the phosphorylated forms of other SFKs due to high 
sequence conservation around the phosphosite. We observed 
that levels of phosphorylated SFKs (pSFK) in HDM ECs 
peaked 10 and 15 min after VEGF165 stimulation, with an 
enrichment of pSFK at CDH5-positive junctions (Fig. 4 C). 
Accordingly, HDM EC monolayers represent a suitable model 
to investigate NRP1-mediated permeability signaling. 
To examine the requirement of NRP1 for VEGF165-me-
diated pSFK induction, we transfected HDM ECs with a previ-
ously validated small interference (si) RNA that targets NRP1 
or a control nonsense siRNA (Raimondi et al., 2014; Fantin et 
al., 2015). Immunoblotting validated NRP1 knockdown effi-
ciency and reduced phosphorylation of the VEG FR2 Y1175 
(pVEG FR2) and the ERK1/2 T202/Y204 (pERK) residues 
after VEGF165 stimulation in NRP1-deficient compared 
with NRP1-expressing cells (Fig. 4, D and E), as previously 
attributed to impaired VEG FR2 trafficking (Lanahan et al., 
2013; Raimondi et al., 2014). Immunoblotting further showed 
Figure 2. VEGF164-induced vascular leakage depends on VEG Fr2, nrP1 and VEGF-binding to nrP1. (A) Evans Blue leaks from the circulation 
into the dermis after intradermal injection of VEGF164, but not PBS; the circles indicate the tissue area around the injection sites that was excised for dye 
extraction. Bar, 1 cm. (B and C) Vegfr2fl/fl (B) and Nrp1fl/fl (C) mice expressing or lacking the endothelial Cdh5-CreERT2 transgene were tamoxifen treated to 
induce gene deletion; immunoblotting of liver (B) or skin (C) lysates with the indicated antibodies (left) confirmed gene deletion, whereas Miles assays with 
PBS versus VEGF164 (right) showed defective VEGF164-induced leakage. (D) Schematic representation of NRP1 mutants with defective VEGF164 binding 
to NRP1. (E–G) Miles assay with PBS versus VEGF164 in mutant and wild-type littermates of the indicated genotypes. Immunoblotting of skin lysates with 
the indicated antibodies (G) showed normal NRP1 levels in Nrp1D320K/D320K mice compared with littermate controls. In B–G, leakage was measured as optical 
density and expressed as fold change relative to PBS, mean ± SEM; n = 5 each (B and G), n = 5 controls, n = 6 mutants (C), n = 8 controls, n = 10 mutants 
(E), n = 4 controls, n = 7 mutants (F); asterisks indicate significant P-values for permeability-inducing agents versus PBS: *, P < 0.05; **, P < 0.01; ***, P < 
0.001; ns, not significant, P > 0.05; paired Student’s t test. Hash tags indicate significant P-values for permeability-induction in mutants versus controls 
(#, P < 0.05; ##, P < 0.01; ns, P > 0.05; unpaired Student’s t test).
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that VEGF165 stimulation increased pSFK levels in control 
HDM ECs, but that this response was attenuated in HDM ECs 
lacking NRP1 (Fig. 4 D). As total SRC levels were increased 
in NRP1-deficient cells (Fig. 4 D), reduced pSFK activation 
was not explained by reduced SRC expression. Quantification 
demonstrated a significant reduction in pSFK activation 10 
and 15 min after VEGF165 stimulation in HDM ECs lack-
ing NRP1 compared with controls (Fig. 4 F; we normalized 
pSFK to GAP DH rather than an individual SFK, because the 
pSFK antibody recognizes the phosphorylated forms of several 
SFKs). Together, these findings suggest that endothelial NRP1 
is essential for VEGF165-induced SFK activation.
VEGF165-induced SFK activation relies on VEG Fr2- and 
nrP1-mediated ABL kinase activation
VEGF165 stimulation activates ABL1 and ABL2 in human 
ECs in vitro, and ABL kinase activation is essential for 
VEGF164-induced vascular permeability in the Miles assay 
(Aman et al., 2012; Anselmi et al., 2012; Chislock and Pend-
ergast, 2013). However, it has not previously been examined 
whether VEG FR2 or NRP1 contribute to SFK activation 
in an ABL kinase-dependent manner. We therefore deter-
mined the regulatory hierarchy of these signaling molecules 
in VEGF165-stimulated HDM EC monolayers. First, we in-
vestigated whether VEG FR2 activation is required for ABL 
or SFK activation by treating HDM ECs with PTK/ZK (Vat-
alanib), a highly specific VEG FR2 inhibitor that abolishes 
VEG FR2 downstream signaling (Wood et al., 2000), but 
does not directly target SRC or ABL kinases (VEG FR2 kd 
62 nM; SRC, YES1, ABL1, or ABL2 kd not detected under 
normal assay conditions, i.e., >10 µM; Wodicka et al., 2010; 
Davis et al., 2011). Immunoblotting confirmed that PTK/ZK 
impaired VEGF165-induced VEG FR2 activation (Fig. 5 A). 
PTK/ZK also abrogated pSFK induction (Fig. 5, A and B), 
consistent with prior work demonstrating a role for VEG FR2 
in SRC activation (Sun et al., 2012; Li et al., 2016).
To determine whether VEG FR2 is involved in ABL ki-
nase activation, we examined the VEGF165-induced phos-
Figure 3. the ncd is required to mediate VEGF164-induced vascular leakage, but does not regulate baseline vascular permeability. (A) 
Schematic representation of mutations that impair NRP1 intracellular activity. (B–E) Miles assay with the indicated substances in mutant and wild-type 
littermates of the indicated genotypes; leakage was measured as optical density and expressed as fold change relative to PBS, mean ± SEM; n = 6 con-
trols, n = 5 mutants (B), n = 7 each (C), n = 5 each (D), n = 4 each (E); asterisks indicate significant P-values for permeability-inducing agents versus PBS 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001; paired Student’s t test), and hash tags indicate significant P-values for permeability-induction in mutants versus 
controls (##, P < 0.01; ns, not significant, P > 0.05; unpaired Student's t test). (F) Evans Blue content in the indicated organs 24 h after systemic injection in 
Nrp1cyto/cyto mice and wild-type littermates. Values are normalized to tissue weight and Evans Blue levels in the blood; mean ± SEM; n = 3 each; ns, P > 0.05; 
unpaired Student’s t test.
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Figure 4. nrP1 loss impairs VEGF165-induced SFK activation in human Ecs. (A and B) Immunostaining of confluent HDM EC cultures in growth medium 
under nonpermeabilizing conditions with an antibody specific for human NRP1 (A) or under permeabilizing conditions with antibodies for CDH5 and NRP1 together 
with DAPI to visualize cell nuclei (B); three independent experiments. Single channels in B are shown separately in grayscale, and the boxed area is shown in higher 
magnification on the right. Bar, 50 µm. (C) Immunostaining of confluent HDM EC cultures under permeabilizing conditions for pSFK together with CDH5 and DAPI after 
serum withdrawal, followed by stimulation with VEGF165 for the indicated times (three independent experiments). The corresponding single pSFK channels are shown 
beneath each panel in grayscale as well as the rainbow pixel intensity scale. Bar, 50 µm. (D–F) Confluent HDM EC cultures transfected with si-control or siNRP1 were 
serum-starved and treated with VEGF165 for the indicated times. Lysates were used for immunoblotting with the indicated antibodies (D), followed by quantification 
of pVEG FR2 (Y1175; E) and pSFK (F) induction relative to tVEG FR2 and GAP DH, respectively. Each of the two vertical lines indicates a group of immunoblots from a 
single gel, with both gels containing aliquots of the same protein lysate. Data for si-control and siNRP1-treated cells are expressed as ratio (E) or fold change, for 
VEGF165 treatment at different time points relative to 0 min (F) mean ± SEM; n = 4 independent experiments; asterisks indicate significant P-values for pSFK induction 
after VEGF165 treatment (*, P < 0.05; **, P < 0.01; paired Student’s t test). Hash tags indicate significant P-values for reduced pVEG FR2 and pSFK levels in siNRP1 versus 
si-control at the corresponding time points (##, P < 0.01; unpaired Student’s t test).
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Figure 5. VEG Fr2 and nrP1 are required for VEGF165-induced SFK activation via ABL1. (A–C) Confluent HDM EC cultures transfected with 
si-control or siNRP1 were serum-starved and treated with VEGF165 for the indicated times. Cultures were also treated with vehicle (-) or PTK/ZK (+) for 
30 min before VEGF165 stimulation. Lysates were used for immunoblotting with the indicated antibodies (A), followed by quantification of pSFK levels (B, 
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phorylation of CRKL on Y207, an ABL kinase target that 
is widely used as readout of ABL kinase activation (Sattler 
and Salgia, 1998). We observed increased pCRKL levels 5 and 
15 min after VEGF165 treatment in control, but not PTK/
ZK-treated cells (Fig. 5, A and B). The requirement of VEG 
FR2 for both ABL kinase and SFK activation agrees with our 
finding that endothelial VEG FR2 is absolutely required for 
VEGF164-induced vascular permeability in vivo (Fig. 2 B). 
NRP1 knockdown also impaired VEGF165-medi-
ated pSFK induction and decreased pCRKL levels (Fig. 5, A 
and C). In contrast to PTK/ZK treatment, however, NRP1 
knockdown reduced pCRKL levels at baseline, i.e., before 
VEGF165 stimulation (Fig.  5  C). Also different to PTK/
ZK treatment, NRP1 knockdown did not prevent the 
VEGF165-induced pCRKL increase, although pCRKL lev-
els remained significantly lower in NRP1-deficient compared 
with control cells at all times (Fig. 5 C). Thus, VEGF165-in-
duced ABL kinase activation depends on VEG FR2 com-
pletely and on NRP1 partially.
As NRP1 interacts with ABL1 and is required for its 
activation in fibronectin-stimulated ECs (Raimondi et al., 
2014), we next determined whether ABL1 is required for 
pSFK and pCRKL induction. For this experiment, we trans-
fected HDM EC with previously validated siRNA for ABL1 
(Raimondi et al., 2014). Similar to NRP1 knockdown, ABL1 
knockdown inhibited pSFK induction after VEGF165 stim-
ulation and decreased overall pCRKL levels, but knockdown 
did not prevent the VEGF164-induced increase in pCRKL 
levels (Fig. 5, D and E). The finding that pCRKL levels are 
similarly reduced and pSFK induction severely compromised 
in cells lacking NRP1 or ABL1 suggests that NRP1-de-
pendent ABL1 activation is required for pSFK activation, 
but that NRP1 is not the sole regulator of ABL kinase-de-
pendent pCRKL induction.
We next asked whether ABL2 cooperates with ABL1 
to mediate the VEGF164-induced pCRKL induction. For 
this experiment, we treated HDM ECs with Imatinib, which 
efficiently targets ABL1 and ABL2, but not SRC, YES1, or 
VEG FR2 (ABL1 kd, 1 nM; ABL2 kd, 10 nM vs. SRC, YES1, and 
VEG FR2 kd, not detected under normal assay conditions, i.e., 
>10 µM; ABL1 IC50, 0.025–0.2 µM vs. SRC IC50 >100 µM; 
Buchdunger et al., 1996; Deininger et al., 2005; Davis et al., 
2011). As expected, Imatinib inhibited pCRKL induction 
without affecting VEG FR2 phosphorylation (Fig.  5, F and 
G’). Moreover, and as observed for NRP1 or ABL1 knock-
down, Imatinib significantly impaired VEGF165-induced 
SFK activation despite its poor specificity for SFKs (Fig. 5, F 
and G). PP2, a dual SFK and ABL kinase inhibitor (Tatton et 
al., 2003), also impaired pSFK induction and additionally sup-
pressed baseline SFK phosphorylation (Fig. 5 F). In contrast, 
neither inhibitor impaired VEG FR2 activation (Fig.  5  F). 
These findings suggest that ABL kinase activity is required for 
VEGF165-induced SFK activation downstream of VEG FR2.
The VEGF164-induced phosphorylation of the 
VEG FR2 Y949 residue (Y951 in humans) is essential to re-
cruit SH2D2A (also known as T cell–specific adaptor, TSAd), 
which then recruits SRC to VEG FR2 for vascular perme-
ability signaling (Sun et al., 2012; Li et al., 2016). Consis-
tent with an important role for NRP1 in VEGF164-induced 
vascular permeability, we observed that VEGF165-induced 
VEG FR2 Y951 phosphorylation was reduced in NRP1-defi-
cient HDM ECs compared with controls (Fig. 5 H).
Collectively, our findings demonstrate that VEGF165 
signals via VEG FR2 in a NRP1 and ABL kinase dependent 
manner to activate SFKs and increase vascular permeability 
(Fig. 5 I).
VEGF164-induced vascular permeability signaling 
via SFKs relies on the ncd
We next determined whether the NCD was required for en-
dothelial pSFK induction. After injection of VEGF164 versus 
PBS into ear dermis, immunoblotting of lysates from tissues 
surrounding the injection site demonstrated that VEGF164 
induced SFK and ERK1/2 phosphorylation in wild-type 
mice, and that this response was impaired in NCD-defi-
cient mice (Fig. 6 A). We next analyzed confluent, nonpas-
left) and pCRKL levels (B’, right, and C) relative to GAP DH (four independent experiments). Each of the two vertical lines indicated a group of immunoblots 
from a single gel, with both gels containing aliquots of the same protein lysate. (D–E) Confluent HDM EC cultures transfected with si-control or siABL1 were 
serum-starved and treated with VEGF165 for the indicated times. Lysates were used for immunoblotting with the indicated antibodies (D), followed by 
quantification of pSFK levels (E, left) and pCRKL levels (E’, right) relative to GAP DH (four independent experiments). Each of the two vertical lines indicates 
a group of immunoblots from a single gel, with both gels containing aliquots of the same protein lysate. The spacer line (D, bottom) separates lanes 4–6 
(left) from lanes 1–3 (right) of immunoblots from the gel in Fig. S1. (F–G) Confluent HDM EC cultures were serum-starved and treated with vehicle, Imatinib 
or PP2 for 30 min before VEGF165 stimulation for the indicated times. Lysates were used for immunoblotting with the indicated antibodies (F), followed by 
quantification of pSFK levels (G, left) and pCRKL levels (G’, right) relative to GAP DH (three independent experiments). Each of the two vertical lines indicates 
a group of immunoblots obtained from a single gel, with both gels containing aliquots of the same protein lysate. In B, E, and G (left) data are expressed 
as fold change, mean ± SEM, in VEGF165-treated cells at 5 and 15 min relative to 0 min; in C and B, E, and G (right), data are expressed as fold change, 
mean ± SEM, in VEGF165-treated cells at 5 and 15 min relative to control cells at 0 min; asterisks indicate P-values for induction after VEGF165 treatment 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001; paired Student’s t test); hash tags indicate significant P-values for different treatments at corresponding time points 
(#, P < 0.05; ##, P < 0.01; ###, P < 0.001; unpaired Student’s t test; n ≥ 3 independent experiments). (H) Confluent HDM EC cultures transfected with si- 
control or siNRP1 and serum-starved were treated with VEGF165 for the indicated times and lysates used for immunoblotting with the indicated antibodies 
(three independent experiments). (I) Model for VEGF165-induced vascular permeability signaling including the point of interference by pharmacological 
inhibitors used in this study.
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saged primary mouse brain ECs (MBECs); immunoblotting 
confirmed that VEGF164 induced VEG FR2 Y1173 phos-
phorylation (corresponding to Y1175 in human VEG FR2). 
Moreover, VEGF164-induced SFK phosphorylation in wild-
type, but not NCD-deficient MBECs (Fig. 6 B). Immunos-
taining and immunoblotting of confluent primary mouse 
lung ECs (MLECs) also confirmed that VEGF164 increased 
pSFK levels in ECs from wild-type, but not NCD-defi-
cient mice (Fig. 6, C and D). Three different assays therefore 
showed that NCD loss impairs VEGF164-induced SFK ac-
tivation. NCD loss also impaired VEGF164-induced CRKL 
activation in MLECs (Fig. 6 E). Together, these findings sug-
gest that the NCD enables VEGF164-induced ABL kinase 
and SFK activation in ECs.
the ncd promotes vascular hyperpermeability, but not 
angiogenesis in neovascular eye disease
To determine whether the NCD contributes to pathological 
vascular leak in the eye, we used a mouse model of choroidal 
neovascularisation (CNV) with pathological vascular changes 
similar to those observed in exudative AMD (Balaggan et al., 
2006). In this model, three laser burns are applied to the reti-
nal pigment epithelium (RPE) to rupture Bruch's membrane, 
causing inflammation and inducing VEGF-dependent CNV 
and vascular leakage (Balaggan et al., 2006). Consistent with 
a role for NRP1 in ocular vascular permeability, NRP1 is 
abundantly expressed in adult retinal and choroidal blood ves-
sels (Fig. 7 A). However, and as observed in other organs, basal 
vascular permeability was unaffected in the retinal and cho-
roidal vasculature of NCD-deficient mice (Fig. 7 B). We next 
injected Evans Blue systemically on day (D) 3 after lasering, 
when VEGF levels peak (Fig. 7 C), but CNV is only just be-
ginning (Balaggan et al., 2006). We confirmed that lesion size 
was similar in Nrp1cyto/cyto and wild-type mice (Fig. 7 D) be-
fore injecting Evans Blue intraperitoneally. After 24 h, Evans 
Blue had extravasated around the laser lesion site at the level 
of the choroid and photoreceptors layers and into the inner 
retina (Fig. 7 D). Despite similar lesion size, dye leakage in 
the retina was significantly reduced in Nrp1cyto/cyto compared 
with wild-type mice (Fig. 7 D). In contrast, neoangiogene-
sis was unaffected in mutants, as histological analysis on D14 
after laser injury showed similar neovascular lesion size in 
both genotypes (Fig.  7  E). Together, these findings suggest 
that the NCD does not promote pathological VEGF-induced 
angiogenesis, but selectively increases VEGF164-induced vas-
cular permeability in adult neovascular eye disease.
dIScuSSIon
NRP1 is a multifunctional protein essential in ECs for vascu-
lar development that is widely studied as a VEGF165 receptor 
(Lampropoulou and Ruhrberg, 2014; Raimondi et al., 2016). 
Whereas VEGF165-binding to NRP1 and complex forma-
tion with VEG FR2 were originally thought to drive angio-
genesis, it was subsequently shown that VEGF164 binding to 
Figure 6. ncd loss impairs VEGF164- 
induced SFK activation in the mouse. (A) 
Nrp1cyto/cyto and wild-type ears were injected 
with VEGF164 or PBS for 20 min and lysates 
used for immunoblotting with the indicated 
antibodies (two independent experiments). (B) 
Confluent MBECs from Nrp1cyto/cyto and wild-
type brains were serum-starved and treated 
with VEGF164 for the indicated time points. 
Lysates were used for immunoblotting with 
the indicated antibodies (left), followed by 
quantification of pSFK relative to GAP DH lev-
els (right). Data are expressed as fold change, 
mean ± SEM, in VEGF164-treated cells at 10 
and 20 min relative to 0 min; n = 3 indepen-
dent experiments; asterisk indicates significant 
P-value for induction after VEGF164 treatment 
(*, P < 0.05; paired Student’s t test); hash tag 
indicates significant P-value for different gen-
otypes at corresponding time point (#, P < 0.05; 
unpaired Student’s t test). (C–E) Confluent 
MLECs from Nrp1cyto/cyto and wild-type lungs 
were serum-starved and treated with VEGF164 
for the indicated times and immunostained 
under permeabilizing conditions using an anti-
body for pSFK (C) or lysed for immunoblotting 
with the indicated antibodies (D and E); cells 
were counterstained with DAPI (two indepen-
dent experiments each). Bar, 50 µm.
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NRP1 makes only a small contribution to physiological an-
giogenesis in mice (Fantin et al., 2014; Gelfand et al., 2014). 
This conundrum was explained by the finding that NRP1 
instead promotes postnatal angiogenesis through essential 
roles in extracellular matrix–induced actin cytoskeleton re-
modeling and TGFβ-modulated delta-notch signaling (Rai-
mondi et al., 2014; Aspalter et al., 2015; Fantin et al., 2015). 
In contrast, the VEGF164-bound NRP1–VEG FR2 complex 
recruits GIPC1 to promote its trafficking into signaling endo-
somes, where it sustains pro-arteriogenic ERK1/2 signaling 
(Lanahan et al., 2013). However, it had not previously been 
examined whether VEGF164 binding to NRP1 or NCD-de-
pendent GIPC1 recruitment contribute to VEGF164-in-
duced vascular permeability, and it was not known whether 
NRP1 plays a role in SFK activation for VEGF164-induced 
vascular permeability. Here, we have shown that NRP1 binds 
VEGF164 to promote VEGF164/VEG FR2-induced vascular 
permeability, independently of GIPC1 (Fig. 3). These find-
ings suggest that the NCD–GIPC1 interaction sustains VEG 
FR2 signaling to achieve high level ERK activation for arte-
riogenesis, whereas the NCD acts independently of GIPC1 
to promote VEGF164-induced VEG FR2 signaling for SFK 
activation (Figs. 4, 5, and 6). Our findings in knock-in and 
knockout mouse models of NRP1 deficiency agree with ear-
lier work in endothelial NRP1 mouse mutants, which had 
identified an essential role for NRP1 in VEGF164-induced 
vascular leakage (Acevedo et al., 2008). Although prior work 
did not determine why VEG FR2 is insufficient for vascular 
permeability induction, we now show that NRP1 is required 
as a VEG FR2 co-receptor to enable ABL-dependent SFK ac-
tivation (Figs. 4, 5, and 6). Moreover, our finding that NRP1 
regulates vascular permeability through ABL kinase activation 
Figure 7. the ncd promotes vascular leakage, but not neovascularisation, in a mouse model of cnV. (A) Adult eye sections immunostained for 
NRP1 and CDH5; nuclei were counterstained with DAPI (two independent experiments); NRP1 staining is shown separately on the right. An extension of the 
squared area is shown at higher magnification in (A’–A’’’); the NRP1 channel is shown separately in (A’’); the DIC image is superimposed in A’’’. RGC, retinal 
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. (B) Evans Blue content in the indicated ocular tissues 
in Nrp1cyto/cyto mice and wild-type littermates; mean ± SEM; n = 3 mice; ns, P > 0.05; unpaired Student's t test. (C) ELI SA shows that VEGF is up-regulated 
in the RPE/choroid of wild-type mice on D3 after laser injury in the CNV model (n = 4) compared with eyes before laser injury (n = 6); data are expressed as 
mean ± SEM; the asterisk indicates a significant increase in VEGF levels on D3 (***, P < 0.001; unpaired Student’s t test). (D) Pathological vascular leakage in 
Nrp1cyto/cyto mice and wild-type littermates. On D3 after laser injury in the CNV model, lesion size was assessed by fundus infrared (IR) imaging (left) before 
Evans Blue was injected intraperitoneally and dye leakage visualized 24 h later in eye sections counterstained with IB4 and DAPI; the Evans Blue single 
channel is shown in grayscale on the right hand side. Leakage into the retina at lesion level (as indicated by red) was quantified as the number of Evans 
Blue–positive pixels integrated for Evans Blue pixel intensity in mutants relative to littermate controls; mean ± SEM; n ≥ 8 mice each; *, P < 0.05 (unpaired 
Student’s t test). (E) Maximum intensity projections of confocal z-stacks through whole mount RPE/choroids from Nrp1cyto/cyto and wild-type littermates 
stained for IB4 on D14 after lasering in the CNV model. Quantification of lesion size (right) as number of IB4-positive pixels integrated for IB4-pixel intensity 
in mutants relative to littermate controls; mean ± SEM; n ≥ 5 eyes each; ns, not significant; P > 0.05 (unpaired Student’s t test). Bars: 25 µm (A); 1 mm (D, 
left); 200 µm (D, right); 200 µm (E).
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also agrees and extends genetic studies implicating ABL ki-
nases in VEGF164-induced vascular permeability (Aman et 
al., 2012; Chislock and Pendergast, 2013) by identifying the 
receptor complex that mediates ABL kinase activation.
A prior study used SU6656 to investigate the regula-
tory hierarchy of SRC and ABL kinase activation in ECs after 
VEGF164 stimulation and placed SRC upstream of ABL ki-
nases (Chislock and Pendergast, 2013). However, this inhibitor 
targets both SRC and YES1, as well as VEG FR2, which resides 
at the top of this signaling cascade, and even targets ABL1, al-
though to a smaller extent (remaining activity at 1 µM: SRC 
31% and YES1 12% vs. VEG FR2 51% and ABL1 77%; Gao et 
al., 2013). Similarly, the SRC inhibitor PP2, which we have 
used here, is not selective for SRC, but has dual SFK/ABL 
kinase specificity (Tatton et al., 2003) and accordingly abro-
gated both VEGF165-induced SFK and ABL kinase activa-
tion (Fig. 5). Results obtained with these inhibitors therefore 
support the idea that the VEG FR2–ABL–SFK axis has a key 
role in VEGF164-induced permeability signaling, but they 
did not define the regulatory relationship of these kinases. In 
contrast, Imatinib does not block VEG FR2 activation (Fig. 5, 
F and G) and has high specificity for ABL kinases over SFKs 
(Deininger et al., 2005; Davis et al., 2011). Our results with 
Imatinib, when combined with those acquired with the VEG 
FR2 inhibitor PTK/ZK, therefore conclusively show that 
VEG FR2 is upstream of ABL kinases, which are upstream of 
SFKs (Fig. 5). These observations agree with those obtained 
with siRNA-mediated knockdown of ABL1 (Fig. 5, D and 
E). Hence, the finding that NRP1 cooperates with VEG FR2 
to enable ABL-dependent SFK activation in an NCD-depen-
dent fashion places several molecules previously reported to 
be essential for VEGF165-induced vascular permeability into 
a well-defined regulatory hierarchy (Fig. 5 I).
The observation that NRP1 forms a complex with 
ABL1 in ECs independently of VEGF165 stimulation (Rai-
mondi et al., 2014) raises the possibility that NRP1 helps 
deliver ABL1 to VEG FR2, once VEGF165 has induced 
complex formation between NRP1 and VEG FR2. In this 
manner, NRP1-bound ABL1 would be able to phosphory-
late SFKs that are recruited to VEG FR2 via SH2D2A, the 
intracellular adaptor protein that binds the phosphorylated 
Y951 residue of VEG FR2 that is required for VEGF164-in-
duced vascular permeability (Sun et al., 2012; Li et al., 2016). 
Supporting this idea, SFK activation by ABL kinases would 
require spatial proximity of both types of proteins, because 
ABL kinases depend on the interaction with their substrates 
to overcome intramolecular autoinhibition (Wang, 2014), and 
such proximity would be instilled when VEGF165 tethers the 
VEG FR2–SH2D2A–SFK and NRP1–ABL1 complexes to 
each other by forming a bridge between its two receptors. 
This model of higher order complex formation between sev-
eral signaling components in the VEGF pathway is consis-
tent with the strong reduction in pSFK levels after NRP1 
or ABL1 knockdown (Fig. 5), as well as our genetic studies, 
which showed that endothelial NRP1 and VEGF164-bind-
ing to NRP1 are both required for a robust permeability re-
sponse (Figs. 2 and 3). Moreover, an important role of the 
NCD in this pathway agrees with prior observations that the 
NCD enhances complex formation of NRP1 and VEG FR2 
in VEGF165-stimulated ECs (Prahst et al., 2008) and pro-
motes ABL1 function in tumor cells (Yaqoob et al., 2012).
Prior work in arterial ECs showed that GIPC1 interacts 
with the NCD to sort the VEGF164-activated VEG FR2 re-
ceptor complex into cellular compartments devoid of phos-
phatases that would otherwise dephosphorylate the VEG FR2 
residue Y1173 (Lanahan et al., 2013). In contrast, our obser-
vation that GIPC1 is dispensable for the VEGF164-induced 
permeability signaling (Fig. 3), which depends on Y949 phos-
phorylation of VEG FR2 (Sun et al., 2012; Li et al., 2016), 
raises the possibility that NCD-mediated intracellular VEG 
FR2 trafficking, even though important to maintain the VEG 
FR2 (Y1173)–ERK1/2 axis, is not important for activation 
of the VEG FR2 (Y949)–ABL–SFK axis. 
Downstream of the VEGF165-induced signal trans-
duction cascade via VEG FR2, different cellular mechanisms 
have been implicated in the induction of vascular leak-
age. For example, VEGF165 has variably been suggested to 
stimulate the formation of vesiculo-vacuolar organelles for 
transcellular leakage (Dvorak et al., 1996; Bates and Harper, 
2002) or disrupt adherens junctions between adjacent ECs 
to increase paracellular leakage (Dejana et al., 2008). For 
paracellular leakage, SFK-mediated FAK activation regu-
lates adherens junction dynamics by promoting the disso-
ciation of CTN NB1 (β-catenin) from CDH5 (Chen et al., 
2012). Whether the NRP1 pathway identified here controls 
VEGF165-induced permeability predominantly by pro-
moting adherens junction breakdown and/or a transcellular 
transport remains to be evaluated.
The residual vascular permeability observed in the Miles 
assay with mice lacking endothelial NRP1, VEGF164-bind-
ing to NRP1, or the NCD may be explained by a low level 
of VEG FR2-mediated permeability signaling, independently 
of NRP1. A possibility to explain this observation may be 
that the NRP1-independent pathway utilizes ABL2 for 
SFK activation, because ABL2 can be activated by VEGF164 
(Aman et al., 2012; Chislock and Pendergast, 2013). Support-
ing the idea that ABL2 can help convey VEGF164-induced 
VEG FR2-mediated permeability signaling, we show here 
that ABL1 knockdown or NRP1 does not completely abolish 
pCRKL induction, whereas the pharmacological VEG FR2 
blockade with PTK/ZK or dual ABL1/ABL2 blockade 
with Imatinib abrogated pCRKL and pSFK induction in re-
sponse to VEGF164 in vitro. Agreeing with a model in which 
VEG FR2 is upstream of both ABL1 and ABL2 activation, it 
has been shown that ABL2 partially compensates for ABL1 
in VEGF164-induced vascular leakage in the Miles assay 
(Chislock and Pendergast, 2013). It remains to be investigated 
how ABL2, which remains active in VEGF164-stimulated 
ECs after NRP1 knockdown, but not VEG FR2 inhibition, 
might be recruited to VEG FR2 during the permeability 
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response. Nevertheless, our finding that VEG FR2 is indis-
pensable for VEGF164-induced SFK activation and vascular 
leakage agrees with prior permeability studies using inhibi-
tors that have VEG FR2 as one of their targets (Murohara et 
al., 1998), a recent study using function-blocking antibod-
ies for VEG FR2 (Hudson et al., 2014) and mouse mutants 
lacking VEG FR2 Y951 phosphorylation (Li et al., 2016). On 
the other hand, NRP1 can convey C-end-Rule peptide- 
mediated leakage independently of VEG FR2 activation 
(Roth et al., 2016), although the precise downstream mecha-
nism remains to be elucidated.
It is presently unclear why NRP1 function-block-
ing antibodies have yielded variable results in disrupting 
VEGF164-induced vascular permeability, with some stud-
ies suggesting a strong inhibitory effect (Becker et al., 2005; 
Teesalu et al., 2009), others observing permeability induction 
(Roth et al., 2016) and others observing no effect (Pan et al., 
2007; Acevedo et al., 2008). One possibility is that the deliv-
ery method or epitopes specificity affect an antibody's ability 
to modulate NRP1 function. Importantly, these limitations 
do not apply to genetic mouse models such as those used in 
the present study, because tissue-specific NRP1 expression 
or NRP1 domain functions have been targeted in a clearly 
defined, uniform, and easily validated manner. Thus, our anal-
yses of intradermal and ocular vascular leakage, as well as 
SFK activation in genetic mouse models conclusively show 
that NRP1 is required for vascular permeability signaling by 
binding VEGF164 and relaying signals through its NCD to 
promote SFK activation. Interestingly, the alternative NRP1 
ligand SEMA3A also induces acute vascular permeability via 
NRP1, but it does not rely on SFK activation (Acevedo et 
al., 2008). Accordingly, the VEGF164 and SEMA3A perme-
ability pathways have been proposed to diverge, despite their 
shared NRP1 dependence. In agreement, we have found that 
the NCD, even though required for VEGF164-induced SFK 
activation and vascular leakage, is dispensable for SEMA3A- 
induced vascular leakage (Fig. 3).
Excessive vascular permeability impairs sight in eye 
diseases such as exudative age-related macular degeneration 
(AMD), diabetic retinopathy, and retinal vascular occlusion 
(Campochiaro, 2015). Although various processes increase 
vascular permeability, pathological leakage in the eye most 
strongly correlates with raised intraocular VEGF (Vinores et 
al., 1997; Rosenfeld et al., 2006; Campochiaro, 2015). Ac-
cordingly, edema in AMD can be significantly reduced with 
anti-VEGF therapies targeting all VEGF isoforms, including 
an anti-VEGF antibody or Fab fragment and a VEGF trap 
(Campochiaro, 2015). Although effective against edema, 
studies in mouse models suggest that global VEGF blockade 
might adversely affect long-term eye health. Thus, reducing 
VEGF levels in the mouse eye compromises the maintenance 
of the choroidal vasculature that is essential for photorecep-
tor health (Saint-Geniez et al., 2009). Moreover, inhibiting 
all VEGF signaling impairs the survival of retinal neurons in 
a mouse model of retinal ischemia, but VEGF120 is capable 
of restoring neuroprotection via VEG FR2 (Nishijima et al., 
2007). An aptamer that selectively targets VEGF165 may pro-
vide an alternative to treat ocular edema when inhibiting all 
VEGF isoforms is not appropriate (Ng et al., 2006), although 
clinical data comparing long term eye safety of this thera-
peutic and the more commonly used pan-VEGF inhibitors is 
not presently available.
Our findings raise the possibility that NRP1-based 
therapeutics might provide an alternative approach to treat-
ing vascular leakage in eye disease when anti-VEGF treat-
ment is not suitable or effective. One possible strategy might 
be to inhibit VEGF165-mediated permeability signaling via 
the NCD or its interactors. This idea is based on our finding 
that NCD-deficient mice have reduced vascular leakage in a 
mouse model of CNV that has several hallmarks of neovas-
cularisation and vascular hyperpermeability in AMD (Fig. 7). 
As NCD loss does not impair physiological angiogenesis 
(Fantin et al., 2011) and does not compromise the survival 
of VEGF164-dependent neurons, at least outside the cen-
tral nervous system (Cariboni et al., 2011), targeting NCD- 
dependent permeability signaling may be particularly useful 
for conditions in which there is a need for VEGF120-me-
diated cytoprotection or the formation of new vasculature, 
such as in the ischemic eye. An alternative strategy to prevent 
ocular vessel leakage may involve targeting both VEGF164 
and SEMA3A signaling via NRP1, in particular in condi-
tions where SEMA3A exacerbates VEGF-induced leakage, as 
has been proposed for the early phase of diabetic macular 
edema (Cerani et al., 2013). As SEMA3A induces vascular 
leakage in the Miles assay via NRP1, but independently of 
the NCD (Fig. 3) or SFKs (Acevedo et al., 2008), reducing 
VEGF165- and SEMA3A-induced leakage would require 
blockade of both ligand-binding domains in NRP1 or inhib-
iting a common downstream target. Future work is therefore 
warranted to investigate whether targeting NRP1-mediated 
signaling is effective in treating edema in the eye or other 
organs to offer a therapeutic approach that preserves the valu-
able vaso- and neuroprotective functions of the VEGF iso-
forms that do not bind NRP1.
MAtErIALS And MEthodS
Study approval
Animal work was performed following UK Home Office 
and institutional Animal Welfare and Ethical Review Body 
(AWE RB) guidelines.
Mouse strains
To create mice with an endothelial-specific NRP1 or VEG FR2 
deletion, we mated floxed conditional Nrp1-null (Nrp1fl/fl; 
Gu et al., 2003) and Vegfr2-null mice (Vegfr2fl/fl) to mice car-
rying the endothelial-specific Cdh5-CreERT2 (Zarkada et 
al., 2015). To induce gene deletion, sex-matched Cre-posi-
tive and Cre-negative young adult littermates were injected 
with 0.5 mg tamoxifen (Sigma-Aldrich) in peanut oil twice 
weekly for 2 wk up until 2 d before performing Miles assays 
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(see following section). Mice carrying one Nrp1-null allele 
(Nrp1+/−), mice with two Nrp1 alleles deficient in VEGF 
binding (Nrp1Y297A/Y297A), NCD-deficient mice (Nrp1cyto/cyto), 
and Gipc1-null mice (Gipc1−/−) have been described previ-
ously (Kawasaki et al., 1999; Chittenden et al., 2006; Fantin 
et al., 2011, 2014). Nrp1D320K/D320K mice carrying a previ-
ously described mutation that abrogates VEGF164 binding 
to NRP1 (Gelfand et al., 2014) were generated with CRI 
SPR/CAS9 technology by the Gene Targeting and Trans-
genic Facility of the University of Connecticut Health Cen-
tre. All mice were maintained on a C57BL/6J background 
(The Jackson Laboratory).
Miles assay
Both flanks of adult anaesthetized mice were shaven. The 
next day, 100 µl of 1% Evans Blue (Sigma-Aldrich) in sterile 
saline (wt/vol) was injected intravenously through the lateral 
tail vein. In some experiments, mice received an intraperito-
neal injection of pyrilamine maleate (4 mg/kg body weight 
in 0.9% saline; Sigma-Aldrich) before Evans Blue injection 
to inhibit release of endogenous histamine. 30 min after 
Evans Blue injection, 20 µl of PBS or PBS containing 50 ng 
VEGF164 (PeproTech), 300 ng SEMA3A (R&D Systems), or 
50 ng histamine (Sigma-Aldrich) were injected intradermally 
each at three sites into the flank skin of anaesthetized mice. 
After 20 min, mice were culled, the skin was separated from 
the underlying muscle, and the tissue surrounding the injec-
tion sites excised (circled in Fig. 1 A) and dried overnight at 
55°C. Evans Blue was extracted by incubation in formamide 
at 55°C overnight and quantified by spectrophotometry at 
620 nm after subtraction of background absorbance at 740 
nm. Data from the three sites injected with the same agent 
(ligand or PBS) were averaged and expressed as fold change 
relative to PBS control per each mouse. In some experiments, 
the inner side of the skin was imaged on an MZ16 stereo-
microscope (Leica) equipped with a Micropublisher camera 
(Perkin-Elmer). In other experiments, a sample of liver or 
skin tissue was retained for immunoblotting.
Baseline permeability assay
100 µl 2% Evans Blue in PBS (wt/vol) was injected intrave-
nously through the lateral tail vein of adult mice and left to 
circulate for 24 h. A blood sample was taken from the heart of 
the anesthetized mice followed by transcardial perfusion with 
1% formaldehyde in PBS containing 0.05 M sodium citrate, 
pH 4.2, prewarmed to 37°C, to clear circulating dye before 
organ collection, dry weight measurement, dye extraction, 
and quantification. Absorbance values were normalized to tis-
sue weight and Evans Blue blood levels, except for the retina 
and RPE/choroid/sclera complex, in which case the value 
per eye tissue was normalized to Evans Blue blood levels.
cell culture
HDM ECs were cultured in MV2 media with supplements 
(Promocell). MBECs were isolated from mice between 1 
and 3 wk of age and cultured on tissue culture plates coated 
with 20 μg/ml FN in EGM2 media (Lonza) without pas-
saging; 4 µg/ml puromycin (Sigma-Aldrich) was included 
in the media for 2 d to eliminate contaminating cell types. 
MLECs were isolated from mice between 1 and 2 mo of age 
by magnetic-activated cell sorting (MACS) with PEC AM1 
and ICAM2 antibodies (BD). MLECs were cultured on 
tissue culture plates coated with 10 µg/ml FN in DMEM- 
GlutaMAX supplemented with 20% FBS, nonessential amino 
acids (Life Technologies), and ECGS (Sigma-Aldrich). Cells 
were stimulated with 50 ng/ml VEGF165 (PeproTech; for 
HDM EC) or VEGF164 (for MLECs or MBECs) for the indi-
cated times. In some experiments, HDM ECs were incubated 
with inhibitors dissolved in DMSO or the same concentra-
tion of DMSO 30 min before VEGF165 stimulation. We used 
the following inhibitors: 10 µM Imatinib (Cambridge Bio-
science), 10 µM PP2 (Sigma-Aldrich), and 0.1 µM PTK/ZK 
(Vatalanib; Selleckchem).
Immunofluorescence
Adult anesthetized mice were transcardially perfused with 
PBS, and then 4% formaldehyde in PBS. Eye and ear tissue 
samples were whole mount immunostained as described pre-
viously (Fantin et al., 2015) using the following primary an-
tibodies: rat anti–mouse PEC AM1 (BD), FITC-conjugated 
mouse anti-SMA (Sigma-Aldrich) or rabbit anti-CDH5 
(from P. Turowski, University College London, London, Eng-
land) and goat anti–rat NRP1 (R&D Systems), previously 
shown to recognize mouse NRP1 (Fantin et al., 2010), fol-
lowed by Alexa Fluor 488–, 594–, or 647–conjugated donkey 
anti–rabbit, anti–rat, or anti–goat secondary antibodies (Jack-
son ImmunoResearch Laboratories). Confocal z-stacks were 
acquired with C-Apochromat 10× 0.45 NA and 40× 1.2 NA 
water objectives a LSM710 laser scanning confocal micro-
scopes (ZEI SS). HDM EC and MLEC were fixed in 4% form-
aldehyde in PBS for 15 min. To detect NRP1 in HDM EC, we 
used mouse anti–human NRP1 (R&D Systems). In some ex-
periments, cultured cells were incubated with the anti-NRP1 
antibody for 5 min before fixation (nonpermeabilizing con-
ditions). We also used goat anti–human CDH5 (Santa Cruz 
Biotechnology, Inc.) and rabbit anti–human pSRC (Cell Sig-
naling Technology). To visualize primary antibodies, we used 
Alexa Fluor 488– or 647–conjugated donkey anti–rabbit or 
anti–goat secondary antibodies (Jackson ImmunoResearch 
Laboratories). Cells were counterstained with DAPI (Sig-
ma-Aldrich) and imaged with a Plan-Apochromat 63× 1.4 
NA oil objective on a LSM700 confocal microscope (ZEI SS). 
Images were processed with Photoshop CS4 (Adobe).
Immunoblotting
Anesthetized mice were injected intradermally with 10 µl PBS 
in one ear and with 10 µl PBS containing 50 ng VEGF164 in 
the other ear. After 20 min, mice were culled, and the ear tis-
sue surrounding the injection site was used for immunoblot-
ting. These ear biopsies, as well as dermis and liver tissue from 
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tamoxifen-treated mice and their littermate controls, was 
homogenized with a pestle, lysed in Laemmli sample buffer, 
and sonicated. Cells were lysed in 50 mM Tris-HCl, pH 7.4, 
5 mM EDTA, 0.1% NP-40, 250 mM NaCl in the presence 
of protease inhibitor cocktail 2 and phosphatase inhibitor 
cocktail (Sigma-Aldrich). Denatured proteins were separated 
by SDS-PAGE and transferred to nitrocellulose membrane 
(Whatman) for immunoblotting with the following primary 
antibodies: rabbit anti–human pVEG FR2-Y1175, rabbit 
anti–human pVEG FR2-Y951, rabbit anti–human VEG FR2, 
rabbit anti-SRC, rabbit anti–human pSRC-Y4169, rabbit 
anti–human pERK1/2-T202/Y204, rabbit anti–rat ERK1/2, 
rabbit anti–human pCRKL-Y207, rabbit anti–mouse AKT, 
rabbit anti-NRP1 (Cell Signaling Technology), rabbit anti–
human GAP DH (Abcam), rabbit anti–human CRKL, and 
goat anti–human CDH5 (Santa Cruz Biotechnology, Inc.).
cnV assay
CNV was induced with a diode laser as previously described 
(Balaggan et al., 2006). In brief, three laser lesions per eye 
were delivered at three disc diameters away from the optic 
nerve head into adult anesthetized mice using a slit-lamp-
mounted diode laser system (Keeler). On D3 post-lasering, 
fundus infrared imaging was performed with a scanning 
laser ophthalmoscope (Heidelberg Spectralis) to ensure 
that lesion size was similar in mutants and controls before 
250 µl Evans Blue (1% in saline, wt/vol) were injected in-
traperitoneally. Eyes were harvested 24 h later, fixed in 4% 
formaldehyde, cryosectioned and stained with biotinylated 
isolectin B4 (IB4; Sigma-Aldrich) followed by Alexa Fluor 
647–conjugated streptavidin (Thermo Fisher Scientific) and 
counterstaining with DAPI. In some experiments, the ret-
inal pigment epithelium (RPE)/choroid complex was dis-
sected on D14 and stained whole mount with IB4. Samples 
were imaged as described above. Retinal vascular leakage was 
measured as density of Evans Blue–positive pixels integrated 
for Evans Blue pixel intensity in maximum projections of 
confocal z-stacks through each lesion. The size of each CNV 
lesion was quantified in maximum projections of confocal 
z-stacks as density of IB4-positive pixels integrated for IB4-
pixel intensity. D14 lesion sizes and D3 lesion leakage were 
averaged for each mouse and expressed as fold change in 
mutants relative to littermate controls.
Statistics
To determine if two datasets were significantly different, we 
calculated the P-value with Excel 12.2.6 (Microsoft Office) 
in two-tailed paired or unpaired Student’s t tests, as described 
in the figure legends; P < 0.05 was considered significant. 
Error bars represent the standard error of the mean, unless 
stated differently in the text.
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